Aspira Pathlab & Diagnostics is a pathology-first diagnostic chain that runs its own labs, not a marketplace - a “new age lab” blending the personal touch of a neighbourhood clinic with the compliance standards of an organised player. The company began life in 1973 as an industrial-products firm and was later reshaped into a technology-driven healthcare provider, now headquartered in Mumbai. Everything it does flows from a single idea: own the lab, control the report, and build trust with doctors and patients in concentrated geographies before expanding further. # Business segments A single engine - pathology and radiology investigations run through owned labs - serving both walk-in patients and hospitals, with a hub-and-spoke model that keeps the balance sheet light. ## 1. Pathology & radiology services: the owned-lab diagnostic engine **Aspira makes money each time a test report is generated in its own facility, with pathology - where samples travel to a central lab - providing the scalability that radiology cannot.** - **Revenue recognised per test, not per contract** - every blood test, X-ray, or health check-up is a separate performance obligation, and the company books revenue at the point in time the report is delivered, net of any discounts. - **Pathology is the scalable half** - pathology tests make up 57% of the diagnostics market and lend themselves to a hub-and-spoke model because samples can be collected anywhere and transported to a central lab for processing, unlike radiology which needs the patient and the machine in the same room. - **Owned labs, not an aggregator** - the company operates its own laboratories and positions this as its quality promise: unlike digital aggregators that route samples to third parties, Aspira stands behind the reliability of every report it issues. - **Asset-light footprint** - the network is built on leased premises with typical agreements of three to five years, and the hub-and-spoke architecture means it does not need a full lab in every location, keeping fixed-asset intensity low. - **B2B is a meaningful sidecar** - hospitals and other healthcare providers contributed just under a third of revenue, though no single customer accounts for more than 10%, so the business is not dependent on any one institutional relationship. ## 2. Patient access layer: the collection-and-convenience front end **Before a sample ever reaches the lab, the company captures demand through home visits, polyclinics, and a mobile app - the physical and digital front doors that feed the diagnostic engine.** - **Home collection brings the lab to the doorstep** - the company provides a home-visit facility for blood sample collection, removing the friction of travel for patients and widening its catchment beyond the immediate neighbourhood of each centre. - **Polyclinics are planned to create walk-in traffic** - by implementing its polyclinic model, Aspira aims to attract greater patient footfall, broadening service accessibility and enhancing operational effectiveness. - **Reports delivered on WhatsApp** - if a patient has not registered an email address, test reports are sent directly via WhatsApp, a low-friction channel that suits the Indian consumer’s mobile-first habits. - **The “Aspira Health” app ties it together** - patients can book tests, download reports, and locate the nearest diagnostic centre through the company’s own mobile app, creating a direct digital relationship rather than relying solely on third-party platforms. - **IT backbone from registration to result** - the entire workflow - specimen registration, bar-coding, payment, analysis, and reporting - is integrated and automated, which reduces manual error and speeds up turnaround. # Group structure and partners **Aspira is a standalone listed entity with no subsidiaries after absorbing its only LLP, and is currently undergoing a promoter-led consolidation of control through a completed open offer.** - **No subsidiary left on the books** - the company’s sole venture, Aspira DNA Diagnostics Gujarat LLP, was acquired on a slump-sale basis effective the end of business on 30th June 2025 and is being wound up, leaving Aspira with no subsidiary, associate, or joint venture as of September 2025. - **Related-party ties to biotech and gaming** - key managerial personnel exercise significant influence over Yashraj Biotechnology Limited and Orangutan Gaming Private Limited, and the board has previously approved an investment of up to ₹1 crore in the gaming entity’s compulsory convertible preference shares. - **Listed on BSE, delisted from MSE** - the equity shares trade on BSE Limited; they were once also listed on the Metropolitan Stock Exchange but have since been delisted from that platform.